Skip to main content
Equibles

ADXN · Addex Therapeutics Ltd.

Track ADXN — free

Use ADXN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADXN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.10 +0.03 (+0.98%)
Rebalance outlook locked
Market Cap
$3.65M
Shares
1.27M
Volume · Oct 5 5873 Avg daily vol (3M) 187.79K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.07 Open$3.01 Day$2.99–3.08 52W close$2.76–10.95 Avg vol 30d285K Short int267 · 0.0% float · 1.0d Short vol19% Last earningsApr 30, 2026 DataFeb 2020–Oct 2026

Up next

Q3 2025 earnings call transcript
call held Sep 30, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$104,710
Trailing 12 months
Net income (TTM)
−$8.66M
Trailing 12 months
Revenue growth YoY
-72.7%
Year over year
Operating margin
-3,130.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.2%
Year over year · more shares
Price change (1Y)
-67.3%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −54%
below
Price vs 50-day avg −31%
below
RSI (14) 39
neutral
MACD trend Positive
52-week position 4%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −17%
trailing
6-month return −57%
trailing
YTD return −60%
this year
Relative strength −70%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow Distributing
-50% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.02% of float · ▼ -93.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score 22
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −75%
past year
ATR 11.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−54% Bearish
Price vs 50-day avg
−31% Bearish
RSI (14)
39 Neutral
MACD trend
Positive Bullish
52-week position
4% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow Distributing
-50% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.02% of float · ▼ -93.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3 Now $3 · 4% Range high $11
vs 200-day avg -54% vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADXN
Addex Therapeutics Ltd.
this stock
$3.65M -60.2% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.0%
Net QoQ
-407 sh
Top holder
UBS Group AG
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
267
Days to cover
1.0d
Change
-3.9K sh
View
Short Volume
Short vol %
19%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.7K
Value
$5.9K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
10.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 2, 2026
This year
15
View
Exempt Offerings
Offering
$3.7M
Filed
Apr 13, 2023
View
Earnings & Events
Webcasts
Last webcast
Apr 30, 2026
View

Performance

5D 20D 120D MTD YTD
ADXN -15.9% -17.3% -57.4% +11.2% -60.2%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -15.7% -16.8% -69.5% +10.3% -73.1%
Key facts CIK 1574232 CUSIP 00654J206 Visit website Investor relations